Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

https://www.meboblog.com/2023/01/denver-tmau-test-survey-tbc-who-it-is.html

Friday, September 9, 2022

Owlstone UK breath test for Trimethylamine ?

Owlstone Medical in UK make 'clinical' breath sensors.


It seems they are working on one for 'chronic kidney disease' that will test 2 biomarkers of interest to the Metabolic Malodor community

1. Trimethylamine
2. Dimethylsulfide

It sounds like it may be a decent TMAU test.
So far it sounds like it isn't used clinically.

Maybe people can write to show interest, and to encourage them to make it a consumer test and perhaps a study for metabolic malodor ?


From the Owlstone blog (30 Aug 22) :

The compounds responsible for the ‘fishy smell’ are now known to be amines, but human breath contains a wide range of other VOCs which could prove to be useful biomarkers for kidney function. A number of recent studies have attempted to investigate the potential clinical value of these VOCs.

Candidate biomarkers
Trimethylamine
Trimethylamine (TMA) is one of the amines that is particularly responsible for the fishy smelling breath associated with kidney disorders. Healthy individuals metabolize TMA in the kidneys, forming urea and formaldehyde. Impaired kidney function allows TMA to build up in the blood stream over time, before being excreted, unmetabolized, on both breath and urine.

This strong link means that in the past TMA in blood plasma has been suggested as a kidney disease biomarker. However, blood sampling is invasive and burdensome, so Grabowska-Polanowska et al. investigated whether measuring TMA on breath could be a better option.3,4 Across two related studies they found TMA on the breath of CKD subjects but not present on the breath of healthy individuals. Other studies, such as Romani et al.’s work, have also adjudged TMA a potential biomarker for CKD.5 Further work is needed to validate an association between TMA levels and disease severity and identify a TMA cutoff value that could be used for diagnosing CKD.

TMA is an exogenous VOC (EVOC) that is present in foods such as fish and normally ingested as part of normal diet. This presents an opportunity for a study to investigate the use of TMA as an EVOC® Probe, in the same way that, at Owlstone Medical, we have explored the utility of limonene (a chemical in orange juice) as an EVOC Probe for liver disease.

...

Dimethyl sulfide
Romani et al.’s study found dimethyl sulfide to be moderately accurate in predicting disease status (AUC 0.740), though Obermeier et al found that patients and controls exhaled similar amounts of dimethyl sulfide.5,6 A possible confounding factor is that organosulfur compounds have been noted to increase as consequence of a subject’s age or concomitant conditions (such as diabetes), not simply CKD status.

Additional classes of VOCs have been tentatively associated with CKD, including amines, alkanes, aldehydes, and alcohols. Further work is required to elucidate the biological associations between VOC marker classes and validate VOC signatures of CKD that can be reliably translated into clinical care.

 

How can we help you?
As interdisciplinary specialists in breath, we have created Breath Biopsy® OMNI to be the most advanced solution for reliable global breath biomarker analysis. And, when you choose to work with us, your investigation is further supported by our extensive study design, management, and data interpretation expertise.

Our Breath Biopsy Collection Station has been developed to maximize your chances of discovering robust breath biomarkers by ensuring optimal sample collection. The ReCIVA® Breath Sampler and CASPER® Portable Air Supply have both been specifically designed to increase signal-to-noise in breath samples (previously a significant challenge), and collect standardized samples that ensure high comparability between patients, even over multiple sampling locations and longitudinal time-courses.

Developing a clinically useful test requires identification of the VOCs that can be linked to underlying biology and the specific disease of interest. Breath Biopsy OMNI uses TD-GC-MS with high resolution and high dynamic range, maximizing the number of VOCs that can be studied in your breath sample.


 

get New Posts by EMAIL : Enter your email address :


A EURORDIS and NORD Member Organization

0 comments:

Post a Comment